Microbix Biosystems Inc
TSX:MBX
Microbix Biosystems Inc
Stock-Based Compensation
Microbix Biosystems Inc
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Microbix Biosystems Inc
TSX:MBX
|
Stock-Based Compensation
CA$654.3k
|
CAGR 3-Years
-3%
|
CAGR 5-Years
34%
|
CAGR 10-Years
8%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Stock-Based Compensation
CA$839.8k
|
CAGR 3-Years
-2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Theratechnologies Inc
TSX:TH
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Stock-Based Compensation
$19.3m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
11%
|
CAGR 10-Years
23%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Spectral Medical Inc
TSX:EDT
|
Stock-Based Compensation
CA$2.8m
|
CAGR 3-Years
20%
|
CAGR 5-Years
20%
|
CAGR 10-Years
25%
|
|
Microbix Biosystems Inc
Glance View
Microbix Biosystems, Inc. engages in developing and commercializing proprietary biological and technology solutions for human health and wellbeing. The company is headquartered in Mississauga, Ontario. The firm manufactures a range of biological materials for the diagnostics industry, notably antigens (Antigen business) used in immunoassays and its quality assessment and proficiency testing controls (QAPs business). The firm operates in two segments: the development, manufacturing, and sales of antigens as materials for the medical diagnostic industry or as quality assessment products (as finished products) and viral transport medium (VTM) and the development and commercialization of products or technologies such as Kinlytic and . The Kinlyti urokinase, which is a biologic thrombolytic drug used to treat blood clots. The firm's catalogue of catalogue covers a range of pathogens that are implicated in maternal, pediatric, childhood, respiratory, sexually transmitted and insect-borne diseases. Its QAPs are available in over 30 countries.
See Also
What is Microbix Biosystems Inc's Stock-Based Compensation?
Stock-Based Compensation
654.3k
CAD
Based on the financial report for Mar 31, 2025, Microbix Biosystems Inc's Stock-Based Compensation amounts to 654.3k CAD.
What is Microbix Biosystems Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
8%
Over the last year, the Stock-Based Compensation growth was -14%. The average annual Stock-Based Compensation growth rates for Microbix Biosystems Inc have been -3% over the past three years , 34% over the past five years , and 8% over the past ten years .
You don't have any saved screeners yet